We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Some of Guidant’s Xience V everolimus-eluting stents did not meet manufacturing standards and the firm voluntarily stopped enrolling new patients in one of its stent trials, the company announced March 29.